Skip to content
AwardedSpainGoods

Suministro de medicamentos biológicos originales y biosimilares basadas en los principios activos adalimumab, trastuzumab, etanercept, rituximab, infliximab y bevacizumab para el Hospital Universitario Miguel Servet de Zaragoza

Published
Published 8 April 2025

Overview

Suministro de medicamentos biológicos originales y biosimilares basadas en los principios activos adalimumab, trastuzumab, etanercept, rituximab, infliximab y bevacizumab para el Hospital Universitario Miguel Servet de Zaragoza

Key details

Country
Spain
Status
Awarded
Category
Goods
Procedure
Selective
Published
8 April 2025
Classification (CPV)
Pharmaceutical products

Award outcome

Awarded value
€346,792
Award date
4 April 2025
Winners
  • ABBVIE SPAIN, S.L.U
  • AMGEN S.A.
  • BIOGEN SPAIN S.L
  • ORGANON SALUD, S.L.,
  • PFIZER SLU
  • SANDOZ FARMACEUTICA, SA

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    8 April 2025

Contracting authority

  • Gerencia Sector Sanitario de Zaragoza 2

    Procuring entity

    Zaragoza, Spain

    ID_PLATAFORMA: 20997630143523

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Suministro de medicamentos biológicos originales y biosimilares basadas en los principios activos adalimumab, trastuzumab, etanercept, rituximab, infliximab y bevacizumab para el Hospital Universitario Miguel Servet de Zaragoza — won by ABBVIE SPAIN, S.L.U +5 — Skim